Related by context. All words. (Click for frequent words.) 87 Patent Infringement Lawsuit 87 Patent Ruling 86 Patent Dispute 86 Patent Suit 86 Patent Infringement Suit 85 Patent Infringement Case 84 Patent Suit Against 83 Patent Infringement Litigation 83 Wins Patent Infringement 83 Patent Lawsuit Against 81 Patent Infringement 81 Settles Patent 81 Infringement Case 80 Files Patent Infringement 80 Patent Infringement Lawsuit Against 80 Patent Suits 79 Settle Patent Litigation 79 Settle Patent 79 Preliminary Injunction Against 79 Antitrust Suit 78 Patent Infringement Action 78 Favorable Ruling 78 Files Patent 78 Antitrust Lawsuit 78 Trademark Dispute 78 Antitrust Case 77 Wins Summary Judgment 77 Receives Favorable Ruling 76 Gets Favorable 76 Settle Litigation 76 Patent Disputes 76 Patent Infringement Claim 76 Arthritis Drug 76 Infringement Suit 76 Countersuit 76 Announce Settlement 76 Infringed 76 Patent Infringement Suit Against 76 Patent Infringement Claims 76 Infringes 75 Receives Favorable 75 Nasdaq Delisting 75 Settle Patent Dispute 75 Legal Dispute 75 Settles Patent Litigation 75 Patent Spat 75 Shareholder Suits 75 Patent Reexamination 75 Announces Favorable 75 Antitrust Probe 75 Files Patent Infringement Suit 74 Settles Charges 74 Antitrust Complaint 74 Announces Favorable Ruling 74 Announces Dismissal 74 Vigorously Defend 74 Settles Litigation 74 Pending Litigation 73 Injunction Against 73 Shareholder Lawsuit 73 Shareholder Suit 73 Patent Litigation 73 Files Patent Infringement Lawsuit 73 Receives Subpoena 73 Files IND 73 Files Countersuit Against 73 Plans Job Cuts 72 Shareholder Lawsuits 72 Suit Vs 72 Cholesterol Drug 72 Licensing Pact 72 Settles Patent Infringement Lawsuit 72 Denies Motion 72 Wins Dismissal 72 Generic Version 72 Narrows 4Q Loss 72 Initiates Patent Infringement 72 Shareholder Lawsuit Against 72 Shares Soar 72 Receives Notification 72 Patent Upheld 72 Gets Favorable Ruling 71 Q4 Profit Plunges 71 Antitrust Settlement 71 Patent Infringement Lawsuits 71 Shares Plummet 71 Posts Wider Loss 71 CFO Resigns 71 Files Lawsuits 71 Jury Verdict 71 Issued Patent 71 Stock Soars 71 Trademark Lawsuit 71 Wider Loss 71 Trademark Infringement Lawsuit 71 Stock Plunges 71 Outlines Strategy 71 Patent Validity 71 Settles Patent Dispute 71 Files Antitrust Suit 71 Lung Cancer Drug 71 Announce License Agreement 71 Begins Shipment 71 Judge Tosses Out 71 Acacia Subsidiary 71 Hostile Bid 71 False Advertising 71 Copyright Infringement Case 71 Permanent Injunction Against 71 Pending Acquisition 71 Whistleblower Suit 71 Suit Filed 70 Unsolicited Proposal From 70 Purported Class 70 Sign License Agreement 70 Dismiss Lawsuit 70 Gets Subpoena 70 Trademark Suit 70 Announces FDA Clearance 70 Restate Results 70 Lawsuit Dismissed 70 Posts 1Q Profit 70 Files Motion 70 Licenses Patents 70 Settles Dispute 70 Ups Ante 70 Antitrust Lawsuit Against 70 Settles Fraud 70 Reaffirms Outlook 70 Confirms Validity 70 Epilepsy Drug 70 Seeks Injunction 70 Drug Fails 70 Q1 Loss Widens 70 Lowers Guidance 70 Derivative Lawsuit 70 Plans Buyback 70 Restate Financials 70 Weight Loss Drug 70 Vioxx Suits 70 Lawsuit Involving 70 Settle Antitrust 70 3Q Loss Widens 70 Discontinues 70 Awarded Patent 70 Drug Coated Stent 70 Restates Earnings 70 Malpractice Suit 70 Milestone Payment 70 Settle Dispute 70 Buyout Rumors 70 Settle Shareholder 70 FDA Clears 70 Gout Drug 69 Court Invalidates 69 Exec Sees 69 Patent Infringements 69 Biotech Firm 69 Generic Versions 69 Lawsuit Brought 69 Options Backdating 69 Suit Alleges 69 Settle Dispute Over 69 Develop Novel 69 Inequitable Conduct 69 Q4 Loss Narrows 69 Suit Settled 69 Q2 Adj 69 Patent Issued 69 1Q Loss Widens 69 Posts 4Q Profit 69 Narrows Loss 69 Backdating Case 69 Antitrust Ruling 69 Achieves Milestone 69 4Q Profit Soars 69 Provides Status 69 Takeover Speculation 69 Analyst Downgrade 69 Reports Wider Loss 69 Blood Thinner 69 Settles Lawsuits 69 Osteoporosis Drug 69 Rehear 69 Nasdaq Delisting Notice 69 Immunomedics Announces 69 Wins Approval 69 Judge Nixes 69 Receives Patent 69 Posts 2Q 69 Completes Tender Offer 69 4Q Loss Widens 69 Drug Maker 69 Submits NDA 69 Wins Injunction 69 Device Maker 69 Boosts Outlook 69 Schizophrenia Drug 69 Antitrust Suit Against 69 FDA Okays 69 4Q Profit Surges 69 Proxy Fight 69 Sell Itself 69 Terminate Merger Agreement 69 Licenses Novel 69 Dismiss Case 69 Antitrust Violations 69 Stock Tumbles 69 Drops Suit 69 Suits Against 69 Announces Immediate Availability 69 3Q Profit Plunges 69 License Pact 69 Unsolicited Tender Offer 69 Trims Loss 69 Teva Provides Update 69 Q2 Loss Narrows 69 Claim Against 69 Non Infringement 69 Files Patent Application 69 FDA Panel Recommends 69 Taro Receives 69 Patents Upheld 69 Infringe 69 Generic Lovenox 68 Migraine Drug 68 Posts 4Q Loss 68 Withdraws Application 68 Narrower Loss 68 Attorneys Fees 68 DVD Copying 68 Clears Path 68 Lawsuit Settled 68 Share Buybacks 68 Analyst Upgrade 68 Receives Approvable Letter 68 Licensing Deal 68 Reverses Loss 68 Complaint Filed 68 Ups Guidance 68 Q3 Loss Widens 68 Beats Forecast 68 Margin Expansion 68 Provides Update Regarding 68 Kickback Case 68 Outlook Disappoints 68 Commenced Against 68 Settlement Reached 68 Posts 2Q Profit 68 Rehearing En Banc 68 Receives Milestone Payment 68 Complaint Against 68 Board Unanimously Rejects 68 Lawsuits Filed 68 Announces Tentative Approval 68 Drug Shows Promise 68 Develop Next Generation 68 Beats Views 68 Completes Patient Enrollment 68 1Q Loss Narrows 68 Analyst Predicts 68 Exec Says 68 Files Provisional 68 Defamation Lawsuit 68 Meets Estimates 68 Receives Orphan Drug Designation 68 Declaratory Judgment 68 2Q Loss Widens 68 Q3 Loss Narrows 68 Settles Patent Suit 68 Q4 Profit Drops 68 Trims Outlook 68 Board Authorizes 68 Injunctive Relief 68 Trademark Infringement 68 Countersues 68 Suit Against 68 Wider Than Expected 68 Earns Milestone Payment 68 Sign Licensing Agreement 68 Trial Halted 68 Beats Expectations 68 Lawsuit Alleges 68 Gets FDA Clearance 68 Q2 Profit Plunges 68 Update# 68 Psoriasis Drug 68 Chip Makers 68 Reaches Settlement Agreement 68 Has Spiked 68 Verdict Upheld 68 Ruling Upheld 68 Earnings Cheat Sheet 68 Refocuses 68 Loses Lawsuit 68 1Q Profit Slips 68 Accounting Errors 68 Settle Suits 68 Resubmit 68 Copyright Infringement Lawsuit 68 Unveils Next Generation 68 NASDAQ Delisting 68 Tops Forecasts 68 Court Reverses 68 Announce Collaboration Agreement 68 Buyout Talks 68 Announces Licensing Agreement 68 Stock Buyback 68 Q1 Profit Drops 68 Amend Merger Agreement 68 Complies With 68 Discrimination Case 68 Lifts FY# Outlook 68 Settle Lawsuits 67 Misses Views 67 Age Bias 67 Fraud Suit 67 Q4 Loss Widens 67 Slashes Price 67 Action Suit 67 Cholesterol Lowering Drug 67 Above Estimates 67 Achieves Significant 67 Shares Climb 67 Patent Invalid 67 Settles Suit 67 Files Suit 67 Court Dismisses 67 Maker Sues 67 Seeks Damages 67 Losses Narrow 67 Buyback Plan 67 Fee Dispute 67 Court Reverses Ruling 67 Found Liable 67 Lawsuit Against 67 Patient Enrollment 67 Whistleblower Lawsuit 67 Lawsuit Settlement 67 FCC Approves 67 Provides Guidance 67 2Q Loss Narrows 67 Terminate Agreement 67 Lupus Drug 67 Significantly Increases 67 Slashes Guidance 67 Q2 Loss Widens 67 Enemy Combatant Case 67 Buyout Bid 67 Can Proceed 67 Legal Setback 67 Pomerantz Law Firm 67 Lowers Outlook 67 Posts 1Q 67 Losses Widen 67 Backs FY# Outlook 67 Cuts Costs 67 Lawsuit Alleging 67 Regulatory Clearance 67 Patent Covering 67 Withdraws Proposal 67 Nearly Triples 67 Submits Application 67 Profit Slips 67 Files Complaint 67 Formalizes 67 Shareholder Derivative 67 Reconfirms 67 Files Trademark 67 Improves Survival 67 Shares Surge 67 Contract Dispute 67 Backs FY# View 67 Shares Tumble 67 Loss Shrinks 67 Upholds Ruling 67 Spears Conservatorship 67 FDA Accepts 67 Delays Filing 67 Profit Dips 67 Extends Collaboration 67 Inhaled Insulin 67 Protects Customers 67 1Q Profit Down 67 Ups Bid 67 Files Patent Suit 67 Lowers Forecast 67 Court Nixes 67 Expand Collaboration 67 Judge Tosses 67 Amplifies 67 Broadens Scope 67 iPhone Exclusivity 67 KB Home Swings 67 Reach Settlement Agreement 67 Quadruples 67 False Marking 67 Extends Leadership 67 Delivers Next Generation 67 Gains Ground 67 Drug Candidate 67 Files Petition 67 Oral Argument 67 1Q Profit Falls 67 Net Loss Narrows 67 Receives Positive 67 Submits Supplemental 67 Q2 Profit Surges 67 Resolve Dispute 67 Resolves Dispute 67 Defends Itself 67 Q1 Profit Soars 67 Successfully Defends 67 Misled Investors 67 4Q Profit Down 67 Action Suit Against 67 Q1 Loss Narrows 67 Q2 Profit Soars 67 Misses Expectations 67 Q3 Profit Jumps 67 Acquire Assets 67 Stock Plummets 67 Piracy Lawsuits 67 Blood Pressure Drug 67 Restate Financial 67 Debuts Next Generation 67 Announces Proposed Settlement 67 4Q Profit Falls 67 CHMP Opinion 67 Commercializes 67 Vacates 67 Posts 2Q Loss 67 Reduces Debt 67 Posts Smaller 67 Spins Off 67 Above Consensus 67 Discrimination Lawsuit 67 Rheumatoid Arthritis Drug 66 3Q Profit Falls 66 Copyright Infringement 66 Trial Nears 66 Previously Disclosed 66 Q4 Profit Surges 66 Case Involving 66 Destroyed Evidence 66 Announce Licensing Agreement 66 Posts 3Q 66 Settles Claim 66 Raises Outlook 66 File Sharing Case 66 Jumps Higher 66 Court Throws Out 66 Completes Enrollment 66 Higher Than Expected 66 Supplemental Biologics License Application 66 Supreme Court Hears 66 Flamel Technologies Announces 66 Announces Job Cuts 66 2Q Profit 66 Defamation Case 66 Files Lawsuit 66 Piracy Crackdown 66 Tops Estimates 66 Explore Strategic Alternatives 66 Delay Filing 66 ONN.tv Report 66 Punitive Damages 66 Reaches Tentative Settlement 66 Case Thrown Out 66 Court Tosses 66 Security Flaw 66 Buy Privately Held 66 Judge Throws Out 66 Below Consensus 66 Reach Settlement 66 Issues Resolved 66 Abandons Bid 66 Boosts Forecast 66 Rejects Appeal 66 Patents Covering 66 Sharpens Focus 66 Shareholder Claims 66 Seek Damages 66 Announce Early Termination 66 4Q Profit Dips 66 Boosts Productivity 66 Q1 Adj 66 Strengthens Position 66 Appeal Ruling 66 Starts Shipping 66 Expand Relationship 66 Reaffirms FY# Outlook 66 Approve Merger 66 First Patient Treated 66 Surpasses Expectations 66 Extends Offer 66 Receives FDA Clearance 66 Posts Loss 66 2Q Profit Down 66 Lawsuit Filed 66 Profit Beats Expectations 66 STRATEGY ANALYTICS 66 4Q Loss 66 Profit Beats Estimates 66 Announce Expiration 66 Launches Generic Version 66 Boosts Buyback 66 Discrimination Suit 66 Significantly Improves 66 Feds Seek 66 Significantly Reduces 66 Reaffirms FY# Guidance 66 Sexual Harassment Case 66 Profits Soar 66 4Q Profit Slips 66 Mylan Receives Approval 66 Generic Version Of 66 Drags Down 66 1Q Loss 66 Extends Tender Offer 66 No. #-# Fed. 66 Faces Delisting 66 Lawsuit Challenging 66 4Q Profit Jumps 66 HSR Waiting Period 66 Multibillion Dollar 66 3Q Profit 66 Introduces Next Generation 66 Patent Troll 66 Posts Strong 66 Justices Weigh 66 Unveils Newest 66 3Q Profit Drops 66 3Q Profit Soars 66 Beats Forecasts 66 Judge Clears Way 66 Chalks Up 66 Key Milestones 66 Profit Soars 66 Signs Licensing Agreement 66 Suits Filed 66 Seeks Buyer 66 Terminates Merger Agreement 66 Widely Used 66 Tops Expectations 66 Q2 Profit Drops 66 Prostate Cancer Vaccine 66 Matches Expectations 66 Settles Suits 66 Settle Lawsuit Over 66 Profit Misses 66 Strengthens Balance Sheet 66 Generic Protonix 66 Issues Statement Regarding 66 Q1 Profit Jumps 66 BioSante Pharmaceuticals Announces 66 Raises Guidance 66 Citi Downgrades 66 Meets Primary Endpoint 66 Remains Neutral 66 Questions Loom 66 #.#B Bid 66 Commercially Available 66 Not Liable 66 Deliver Powerful 66 Airwaves Auction 66 Successfully Completes Tender Offer 66 Slowing Growth 66 Domain Name Dispute 66 Settle Fraud 66 Sign Definitive Agreement 66 Million Verdict 66 Results Disappoint 66 1Q Profit 66 Announces Stockholder Approval 66 Claim Filed 66 Expects 1Q 66 2Q Loss 66 Request Denied 66 Files Formal 66 Guides Inline 66 Exec Resigns 66 Misses Estimates 66 4Q Profit Drops 66 Fortifies 66 Restates Results 66 Inks License 66 Settle Lawsuit 66 Court Hears Arguments 65 #cv# [003] 65 Settle Differences 65 Earnings Soar 65 Appeals Court Upholds 65 Q3 Adj 65 Posts Wider 4Q Loss 65 Abandons Plans 65 Shows Promising 65 Tax Evasion Case 65 Unveils Revolutionary 65 Patent Infringement Complaint 65 Suit Challenging 65 Nears Settlement 65 3Q Loss 65 Seeks Approval 65 Investigation Relating 65 Outsells 65 Anemia Drug 65 Bumps Up 65 Piracy Suit 65 2Q Profit Up 65 Newly Identified 65 Antitrust Scrutiny 65 Accelerate Commercialization 65 Posts 3Q Profit 65 Unsolicited Proposal 65 Dividend Hike 65 Being Studied 65 Obtains Exclusive Rights 65 Shows Promise 65 Q3 Profit Drops 65 2Q Profit Drops 65 Delivers Comprehensive 65 Receives CE Marking 65 Initiates Enrollment 65 Receives Unsolicited 65 Tops Views 65 Lower Than Expected 65 Revises FY# Outlook 65 Q3 Profit Soars 65 Restate Earnings 65 3Q Profit Down 65 Q4 Profit Declines 65 Lawsuit Filed Over 65 Cross Licensing Agreement 65 Rejects Request 65 Investigates Claims 65 Faces Suit 65 Regains Full 65 Low Dose 65 Invoke Fifth Amendment 65 Antitrust Clearance 65 Anemia Drugs 65 Files Voluntary 65 Q2 Profit Plummets 65 #cv# [001] 65 Seeks Dismissal Of 65 Planned Acquisition 65 Cholesterol Drugs 65 Testosterone Patch 65 Denies Bid 65 Profits Drop 65 Boost Profits 65 Jury Decides 65 Takeover Talk 65 Settles Patent Lawsuit 65 Dismiss Charges 65 Develop Innovative 65 3Q Profit Jumps 65 Refile 65 Confirmatory Phase 65 Device Makers 65 Suit Alleging 65 Jointly Announce 65 Beat Estimates 65 Revenues Decline 65 2Q Profit Surges 65 Rehearing 65 Judge Upholds 65 Receives Notice From 65 Judge Overturns 65 Has Filed 65 Insulin Pen 65 Resubmits 65 Billion Buyback 65 Coughs Up 65 Obtains Exclusive License 65 RealMoney Radio Mailbag 65 Action Lawsuits 65 Slashes Prices 65 Hiring Spree 65 Introduces Enhanced 65 Demonstrates Commitment 65 Updates Guidance 65 Execs Plead Guilty 65 Spying Case 65 Posts Narrower Loss 65 Court Dismisses Lawsuit 65 FDA Approvals 65 Case Dismissed 65 Officially Released 65 More Than Doubled 65 Diet Pill 65 3Q Profit Surges 65 Legal Woes 65 Unveil Next Generation 65 Expanded Indication 65 Posts Solid 65 Heartburn Drugs 65 Action Lawsuit 65 Halts Sale 65 Q4 Adj 65 Reaches Settlement 65 Dismiss Suit 65 Faces Lawsuit 65 Settles Lawsuit 65 Q4 Profit Slips 65 Profit Plunges 65 Multimillion Dollar 65 Amends Agreement 65 Wizzard Software Announces 65 Hear Arguments 65 Momentum Continues 65 Raises Bid 65 Q3 Profit Plunges 65 Restructures Debt 65 Lawsuit Dismissal 65 Reveals Positive 65 Spins Out 65 Profit Sinks 65 3Q Profit Up 65 Clinical Trial Results 65 Drug Makers 65 Receives Clearance 65 Court Overturns 65 Testosterone Gel 65 Posts Profit 65 Files Amended 65 Confirms Receipt 65 PDUFA Date 65 Issues Guidance 65 Q4 Profit Soars 65 Announces Discontinuation 65 Court Reinstates 65 Neutral Analyst Blog 65 NASDAQ Listing Requirements 65 Wrongful Death Case 65 Signs License Agreement 65 Finalize Agreement 65 Review Strategic Alternatives 65 Submits IND 65 3Q Loss Narrows 65 OxyContin Maker 65 Continues Momentum 65 Gets Upgraded 65 Sees Positive 65 Announces Definitive Agreement 65 Expects 4Q 65 Profit Exceeds Estimates 65 Suit Accuses 65 Exceeds Estimates 65 Settle Suit 65 IND Application 65 Tentative Settlement 65 Nears Deal 65 Partial Settlement 65 File Swapping 65 Markman Hearing 65 Announces License Agreement 65 Sets Precedent 65 Awarded Patents 65 Present Preclinical Data 65 Buyout Deal 65 Net Neutrality Debate 65 Profit Misses Estimates 65 Narrows Guidance 65 Revenue Climbs 65 Expands Portfolio 65 Case Settled 65 Gets Sued 65 Malpractice Lawsuit 65 NDA Submission 65 Could Trigger 65 Shares Plunge 65 Liver Toxicity 65 Quarterly Loss Widens 65 Q1 Profit Plunges 65 Boosts Profit 65 Milestone Payment From 65 Halts Production 65 Lawsuit Vs 64 FTC Clears 64 Hikes Dividend 64 Cites Positive 64 Exploring Strategic Alternatives 64 Broadens Its 64 Earnings Disappoint 64 Merger Talks 64 Share Buyback 64 Effectively Treats 64 Reduces Risk 64 Faces Setback 64 Significantly Reduced 64 Withdraws Offer 64 Revises Third Quarter 64 Boosts Profits 64 RealMoney Radio Recap 64 Initiates Clinical Trials 64 Initiates Clinical Trial 64 Critical Flaw 64 Boosts Dividend 64 Nanophase Announces 64 Leans Toward 64 Pushes Back 64 4Q Loss Narrows 64 2Q Profit Soars 64 Hits Milestone 64 Files Antitrust Lawsuit 64 Initiates Phase III 64 Deliver Innovative 64 Exec Pleads Guilty 64 Gene Variants 64 Applauds FCC 64 Higher Margins 64 Collaborators Publish 64 Quarterly Loss 64 Fourth Quarter Profit Drops 64 4Q Profit 64 Gets Clearance 64 Dramatically Increases 64 Settles FTC 64 Acne Drug 64 Cross License Agreement 64 Counterclaims 64 Defamation Suit 64 Exec Admits 64 Shows Weakness 64 Novel Oral 64 ANADIGICS Announces 64 Optimistic Outlook 64 Tremendous Growth 64 Court Vacates 64 Lowers Price 64 Phase 1b Clinical Trial 64 Exec Testifies 64 Litigations 64 Q3 Profit Surges 64 Antitrust Approval 64 Reduces Size 64 Seeks Delay 64 #.#B Vioxx 64 XM Sirius Merger 64 Initiates Dosing 64 Topical Treatment 64 Seek Dismissal 64 Stronger Warnings 64 Narrows 2Q 64 Below Estimates 64 Regains NASDAQ 64 Milestone Payments 64 Beats Estimates 64 Sex Discrimination Case 64 Bulks Up 64 Restates 64 Carotid Artery Stenting 64 Loss Widens 64 Resolves Litigation 64 Stem Cell Patents 64 Introduces Revolutionary 64 Profit Doubles 64 Stays Neutral 64 Lawsuit Dismissed Against 64 Collaborates With 64 Goes Offline 64 Appeals Upholds 64 Sees 3Q 64 Loss Narrows 64 Morphs Into 64 Upholds 64 Moves Towards 64 Damages Claim 64 Demonstrates Significant 64 Harassment Case 64 Offers Glimpse 64 3Q Profits 64 Builds Momentum 64 2Q Profit Dips 64 Ruling Expected 64 Sweetens Bid 64 Fraud Suit Against 64 Toshiba Develops 64 Favorable Decision 64 Data Suggest 64 Initiate Phase III 64 Merge Healthcare Announces 64 Receives Complete Response 64 Breaks Barriers 64 Significantly Improved 64 Sued Over Alleged 64 Expands Scope 64 Buyout Offer 64 Initiates Phase II 64 Retools 64 Libel Suit 64 Forecast Quick Facts 64 Deliver Breakthrough 64 Not Disclosed 64 Profits Plunge 64 Mad Money Mailbag 64 Feds Probing 64 Mulls Sale 64 Regarding Proposed Acquisition 64 Conspiracy Charges 64 Integra LifeSciences Announces 64 Slashes Outlook 64 Suit Dismissed 64 Tossed Out 64 Posts Quarterly 64 Conceals 64 Acquire Privately Held 64 Files Suit Against 64 Profit Disappoints 64 Gets Reprieve 64 Prevails 64 Witness Testifies 64 Shareholder Sues 64 Q1 Profit Slips 64 Appeal Denied 64 Tosses Out 64 Posts Better Than 64 Tops Ests 64 Phil Spector Murder Trial 64 Quarterly Profit Drops 64 Graphics Chips 64 Dismisses Claims 64 Drops Sharply 64 Reports 4Q Loss 64 Raises Forecast 64 Posts 3Q Loss 64 Deliver Comprehensive 64 TiVo Posts Narrower 64 Lifts Dividend 64 Asset Swap 64 Fully Functional 64 Permanent Injunction 64 Shareholder Investigation 64 Pending Merger 64 Postpones Annual Meeting 64 Wrongful Death Lawsuit Filed 64 Judge Declares Mistrial 64 Reverses Decision 64 Extend Partnership 64 Negative Feedback 64 * vwd BUSINESS WIRE 64 Sirius XM Merger 64 Issues Clarification 64 Announce Merger Agreement 64 Waiver Request 64 Revises FY# Guidance 64 Dramatically Expands 64 Wins Injunction Against 64 Q1 Profit Declines 64 Momentum Builds 64 Higher Expenses 64 Court Overturns Ruling 64 Unveils Groundbreaking 64 Significant Milestone 64 Achieves Positive 64 Presents Preclinical Data 64 Guides Q2 64 Lowers FY# Outlook 64 Further Strengthens 64 Achieves Record Revenue 64 Suit Claims 64 Legal Tussle 64 Exec Leaves 64 Sniper Suspect Trial 64 Remands 64 Execs Face 64 Provides Preliminary 64 Sees Profit 64 Jury Selection Starts 64 Enable Next Generation 64 Study Demonstrates 64 IND Filing 64 Brain Damaged Woman 64 Settle Probe 64 Terminates Agreement 64 Unveils Expanded 64 Probe Update1 64 Regains Compliance 64 Denies Allegations 64 Begins Tender Offer 64 Expert Testifies 64 Files Lawsuit Against 64 2Q Profit Jumps 64 Be Appealed 63 Leaps Ahead 63 Tablet Device 63 Delays Ruling 63 Informal Inquiry 63 Makes Strides 63 Dramatically Reduces 63 Confirms Commitment 63 Lowers 3Q 63 Appeals Affirms 63 Midday Trading 63 Q2 Profit Declines 63 Obscenity Case 63 Differentiates